Navigation Links
Arena Pharmaceuticals' Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
Date:10/12/2009

A standardized program of moderate diet and exercise guidance is included in the Phase 3 program. The program's hierarchically ordered co-primary efficacy endpoints are: the proportion of patients achieving 5% or greater weight loss after 12 months, the difference in mean weight loss compared to placebo after 12 months, and the proportion of patients achieving 10% or greater weight loss after 12 months. Arena is also studying several key secondary endpoints, including changes in serum lipids, markers of inflammation and insulin resistance, and in the BLOOM-DM trial, other indicators of glycemic control.

About Lorcaserin

Lorcaserin is a novel single agent that represents the first in a new class of selective 5HT-2C receptor agonists. The 5HT-2C receptor is expressed in the brain, including the hypothalamus, an area involved in the control of appetite and metabolism. Stimulation of this receptor is strongly associated with feeding behavior and satiety. Arena has patents that cover lorcaserin in the US and other jurisdictions, which in most cases are capable of continuing into 2023 without taking into account any patent term extensions or other exclusivity Arena might obtain.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for weight management. Arena has a broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, which includes compounds being evaluated independently and with partners, including Merck & Co., Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Arena Pharmaceuticals® and Arena® are registered se
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... CHAPEL HILL, N.C. , Dec. 19, 2014 ... how to optimize a product,s web presence to ... critical. Brand websites, in particular, must meet the ... in regulations and culture. According ... LLC, more than half of the participating companies ...
(Date:12/19/2014)...  Monarch America Inc. (OTCQB: CANK) ("Monarch America" or ... provide this review of the Company,s recent achievements and ... "Over this past year, we achieved many of our ... to say that Monarch America is in a stronger ... been," stated Eric Hagen , CEO of Monarch ...
(Date:12/19/2014)... , December 18, 2014 ... software application/module that is used to store, manipulate, ... RIS comprises a patient tracking and scheduling system, ... integration of RIS with HIS and other databases ... patient registration and patient scheduling, patient list management, ...
Breaking Medicine Technology:Building a Best-in-Class Pharma Global Brand Website 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 3
... 2 MedAvante, Inc., the leader in centralized evaluation of central nervous ... Service for trials assessing Alzheimer,s Disease. Its CQC Services are already in use ... in the United States , Europe , Asia , ... , , ...
... HARBIN, China , June 2 /PRNewswire-Asia-FirstCall/ ... a,developer, manufacturer and distributor of botanical products,bio-pharmaceuticals and traditional Chinese ... a conference call at 9:00 a.m. Eastern Time ... for the second quarter of its,fiscal year 2010, ended ...
Cached Medicine Technology:MedAvante Launches Service to Boost Reliability of Assessments to Reduce Risk of Failed Alzheimer's Disease Trials 2MedAvante Launches Service to Boost Reliability of Assessments to Reduce Risk of Failed Alzheimer's Disease Trials 3Renhuang Schedules Conference Call to Discuss FY 2010 Second Quarter Results 2Renhuang Schedules Conference Call to Discuss FY 2010 Second Quarter Results 3
(Date:12/21/2014)... 2014 Weddingshe.com, an outstanding online supplier ... recently released its new selection of Cocktail Dresses for ... according to the newest fashion trends. , ... for cocktail parties . All of them are offered ... We are making every effort to offer a nice ...
(Date:12/21/2014)... 21, 2014 Hundreds of Byetta ... claims involving a class of Type 2 diabetes ... forward in a federal multidistrict litigation now underway ... Bernstein Liebhard LLP reports. According to an Order ... data cut-off date of February 27, 2014 for ...
(Date:12/21/2014)... Serious Buyer, Andrew Hawley from Vintage Rock ... the Doors International Ballroom at the Hilton Hotel in ... only time that Morrison's mother would see her son ... According to Hawley, “This would be the Doors only ... Roller Rink earlier that year and would return to ...
(Date:12/21/2014)... As testosterone therapy lawsuit filings on ... clots from using testosterone products such as AndroGel and ... the male hormone testosterone may increase the risk of ... the Proceedings of the National Academy of Sciences in ... male rats with naturally occurring colon cancer. Dr. Amos-Landgraf, ...
(Date:12/20/2014)... 2014 BambooIndustry.com is a ... business has announced its bamboo flooring promotion for ... material from certified suppliers, and offers the best ... In the current promotion, all customers can enjoy ... they say they know BambooIndustry.com from press releases. ...
Breaking Medicine News(10 mins):Health News:Stunning Cocktail Party Dresses from Weddingshe.com 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 3Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 4Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2
... agents have a demonstrated efficacy in children with Attention-deficit/hyperactivity ... single pharmacologic agent. A recent study by Dr. Timothy ... issue of the Journal of the American Academy ... first randomized placebo-controlled trial designed to assess efficacy and ...
... 8, 2012. John DeLuca, PhD, VP for Research at Kessler ... Changes in MS," on Tues., January 24, 6:30-7:30 pm. Dr. ... cognition and multiple sclerosis and is a licensed psychologist in ... Jeffrey Gingold, author of, "Facing the Cognitive Challenges of Multiple ...
... the Translational Genomics Research Institute (TGen) have begun to ... lung cancer in never-smokers a first step in ... point. We certainly have a lot of pathways and ... interested in confirming and looking at in larger cohorts ...
... , FRIDAY, Jan. 6 (HealthDay News) -- Inflammatory bowel ... to a new study. Researchers who analyzed data from ... found that the rate of new cases is increasing or ... been studied. Canada and Europe had the highest number of ...
... Early diagnosis and treatment of breast cancer-related lymphedema by ... need for intensive rehabilitation, according to an article published ... (PTJ), the scientific journal of the American Physical Therapy ... member and spokesperson Nicole Stout, PT, MPT, CLT-LANA, compared ...
... Reporter , FRIDAY, Jan. 6 (HealthDay News) -- If the ... (ADHD) has left you searching for something else for your ... because the effects of these medications can vary widely. ... [how much of the drug is absorbed into the bloodstream], ...
Cached Medicine News:Health News:Combination therapy shows positive response for children with ADHD 2Health News:TGen researchers map potential genetic origins, pathways of lung cancer in nonsmokers 2Health News:As Nations Develop, So May Bowel Disease 2Health News:Prospective surveillance model emerges as standard of care for breast cancer treatment 2Health News:ADHD Drug Shortage Pushes Parents to Seek Substitutes 2Health News:ADHD Drug Shortage Pushes Parents to Seek Substitutes 3
The ReSeeVit Slit Lamp System is an easy-to-use digital video imaging system that captures anterior segment and retinal images for documentation, diagnosis and patient education. The package includes...
... slit lamp is a ... that is designed with ... and has standard 10X ... design provides increased optical ...
... is designed to for use with digital ... offers the popular horizontal style light source. ... family of slit lamps that offers the ... clear, crisp digital images in the most ...
... The first slit lamp truly designed ... for digital video imaging. No other slit ... features of this exceptional product. The ReSeeVit ... product on the market to allow capture ...
Medicine Products: